Theratechnologies Inc. (NASDAQ:THTX) Sees Significant Increase in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 72,200 shares, a growth of 64.8% from the November 30th total of 43,800 shares. Based on an average trading volume of 72,500 shares, the short-interest ratio is presently 1.0 days. Approximately 0.4% of the company’s stock are sold short.

Theratechnologies Stock Performance

Shares of THTX traded down $0.04 on Friday, reaching $1.79. The stock had a trading volume of 100,697 shares, compared to its average volume of 52,512. The firm has a market capitalization of $82.30 million, a price-to-earnings ratio of -17.90 and a beta of 1.42. The company has a 50-day simple moving average of $1.38 and a 200-day simple moving average of $1.35. Theratechnologies has a 12-month low of $1.08 and a 12-month high of $2.58.

Theratechnologies (NASDAQ:THTX) last announced its earnings results on Thursday, October 10th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $22.60 million for the quarter. During the same quarter in the previous year, the business posted ($0.03) EPS. On average, analysts expect that Theratechnologies will post 0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Theratechnologies

A hedge fund recently raised its stake in Theratechnologies stock. National Bank of Canada FI increased its stake in Theratechnologies Inc. (NASDAQ:THTX) by 29.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 186,815 shares of the company’s stock after buying an additional 42,435 shares during the period. National Bank of Canada FI owned 0.41% of Theratechnologies worth $232,000 as of its most recent filing with the Securities & Exchange Commission.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.